People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2015 |
| Civitas Therapeutics, Inc. | — | Biotechnology | Series C | $117.8M | $2.3B | 2014 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.2M | 2018 |
| Akero Therapeutics, Inc. | — | Pharma | Series C | $45.5M | $1.6B | 2018 |
Mark Iwicki at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Iwicki on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 2 | 15 |
| Andrea Franz | 2 | 4 |
| Robert Langer | 1 | 36 |
| Steven Gillis | 1 | 23 |
| David Hirsch | 1 | 16 |
| Timothy Shannon | 1 | 9 |
| SCOTT ROCKLAGE | 1 | 9 |
| Terrance McGuire | 1 | 9 |
| Michael Higgins | 1 | 9 |
| Robert Tepper | 1 | 7 |
| Aaron Royston | 1 | 7 |
| Robert Clarke | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Amit Munshi | 1 | 5 |
| Kurt Graves | 1 | 5 |
| DAVID LAZAR | 1 | 5 |
| Howard B. Rosen | 1 | 4 |
| PETER COUROSSI | 1 | 4 |
| MICHAEL J. HIGGINS | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.